DJIA 18,041.54 -190.48 -1.04%
NASDAQ 5,032.75 -56.61 -1.11%
S&P 500 2,104.20 -21.86 -1.03%
market minute promo

Eli Lilly & Co. (NYSE: LLY)

74.31 0.01 (0.01%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

LLY $74.31 0.01%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $73.96
Previous Close $74.30
Daily Range $73.82 - $74.37
52-Week Range $58.50 - $77.46
Market Cap $82.5B
P/E Ratio 36.24
Dividend (Yield) $2.00 (2.7%)
Ex-Dividend Date
Dividend Pay Date
05/14/15
06/10/15
Volume 4,188,288
Average Daily Volume 3,876,197
Current FY EPS $3.15

Sector

Healthcare

Industry

Drug Makers

Eli Lilly & Co. (LLY) Description

The Company discovers, develops, manufactures and sells products in one of its business segment of pharmaceutical products to prevent and treat human diseases. Website: http://www.lilly.com/

News & Commentary

Could Incoming Threats Sink MannKind Corporation?

Big Pharma suspected that MannKind's Afrezza would make its way to the market eventually. Now that its here, what does the industry have in its pipeline that could potentially slow adoption?

Abbvie Inc. Dividend Stock Analysis

A Review Of Amgen's AMG 334

New Issue- Eli Lilly prices a triple tranche deal

3 Stocks Poised to Grow in the Schizophrenia Market - Analyst Blog

3 Stocks Poised to Grow in the Schizophrenia Market - Analyst Blog

Insider Trading Alert - LTBR, LLY And AGCO Traded By Insiders

Jefferies Makes Changes to Top Pharmaceutical Stocks to Buy

Insider Trading Alert - MSFT, PMT And LLY Traded By Insiders

Notable ETF Inflow Detected - DGRW, MCD, BMY, LLY

4 Reasons Why MannKind Could Succeed Where Pfizer Failed

9 years ago Pfizer tried to launch an inhaled insulin called Exubera to the market and it failed. Here are 4 reasons why Afrezza could succeed where Pfizer came up short.

See More LLY News...

LLY's Top Competitors

LLY $74.31 (0.01%)
Current stock: LLY
JNJ $100.82 (-0.52%)
Current stock: JNJ
NVS $101.81 (-1.96%)
Current stock: NVS
RHHBY $36.24 (-1.62%)
Current stock: RHHBY